Claims
- 1. Compounds of the formulae: ##STR7## wherein Z is thio, sulfinyl, or sulfonyl;
- R.sup.1 and R.sup.2 are independently hydrogen, halogen, amino, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkylthio, C.sub.1 to C.sub.4 alkoxy, thiol, C.sub.1 to C.sub.4 alkylsulfinyl, C.sub.1 to C.sub.4 alkylsulfonyl, trifluoromethyl, trifluoromethylthio, cyano, nitro, C.sub.1 to C.sub.5 alkyl having one of the hydrogens replaced by phenyl, halophenyl, nitrophenyl, aminophenyl or loweralkylphenyl, hydroxyloweralkyl, C.sub.1 to C.sub.4 alkylamino, dialkylamino wherein each alkyl group has 1 to 4 carbons;
- X is O, N--R.sup.3, wherein R.sup.3 is hydrogen, C.sub.1 to C.sub.4 alkyl, phenyl, halophenyl, nitrophenyl, aminophenyl, hydroxyphenyl, loweralkylphenyl, hydroxy, C.sub.1 to C.sub.4 alkoxy, C.sub.1 to C.sub.5 alkanoyloxy, amino, C.sub.1 to C.sub.4 alkylamino or dialkylamino wherein each alkyl group has 1 to 4 carbons; and the pharmaceutically acceptable salts thereof.
- 2. A compound according to claim 1, said compound having the Formula IA wherein Z is sulfinyl or sulfonyl, R.sup.2 is hydrogen and R.sup.1 is at position 8 or 9 and is fluoro, chloro, bromo, amino or hydrogen, or said compound having the Formula I wherein Z is sulfinyl or sulfonyl, R.sup.2 is hydrogen and R.sup.1 is at position 2 or 3 and is fluoro, chloro, bromo, amino or hydrogen.
- 3. A compound according to claim 1, said compound having the Formula IA wherein Z is sulfinyl or sulfonyl, R.sup.2 is hydrogen, R.sup.1 is at position 8 or 9 and is fluoro, chloro, bromo, amino, or hydrogen, and X is oxo, or said compound having the Formula I wherein Z is sulfinyl or sulfonyl, R.sup.2 is hydrogen, R.sup.1 is at position 2 or 3 and is fluoro, chloro, bromo, amino or hydrogen, and X is oxo.
- 4. A compound according to claim 1, said compound having the Formula IA wherein Z is sulfonyl, R.sup.2 is hydrogen and R.sup.1 is at position 8 or 9 and is fluoro, chloro, bromo, amino, or hydrogen, and X is oxo, or said compound having the Formula I wherein Z is sulfonyl, R.sup.2 is hydrogen, R.sup.1 is at position 2 or 3 and is fluoro, chloro, bromo, amino or hydrogen, and X is oxo.
- 5. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11,11-dioxide.
- 6. The compound of claim 1 which is: 8-fluoro-6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11,11-dioxide.
- 7. The compound of claim 1 which is: 9-fluoro-6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11,11-dioxide.
- 8. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11,11-dioxide.
- 9. The compound of claim 1 which is:. 2-fluoro-6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11,11-dioxide.
- 10. The compound of claim 1 which is: 3-fluoro-6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11,11-dioxide.
- 11. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11-oxide.
- 12. The compound of claim 1 which is: 8-Fluro-6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11-oxide.
- 13. The compound of claim 1 which is: 9-Fluoro-6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde-11-oxide.
- 14. The compound of claim 1 which is: 3-Fluoro-6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11-oxide.
- 15. The compound of claim 1 which is: 2-(N-phenyliminomethyl)-6H-dibenz[b,e][1,4]oxathiepin-10,11-dioxide.
- 16. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde.
- 17. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-2-carboxaldehyde.
- 18. The compound of claim 1 which is: 6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11-oxide.
- 19. The compound of claim 1 which is: 2-fluoro-6H-dibenz[b,e][1,4]oxathiepin-9-carboxaldehyde-11-oxide.
- 20. A pharmaceutical composition for treating or controlling allergic conditions or thromboembolic diseases in a mammal comprising a pharmaceutically-effective amount of a compound of claim 1.
- 21. A pharmaceutical composition according to claim 20 additionally comprising an effective amount of a second active ingredient selected from the group consisting of indomethacin, ibuprofen, sulindac, fenbufen, zomepirac, diflunisal, benadryl, dramamine, histadyl, phenergan, captopril, N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline, N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl-L-proline and N-.alpha.-(1-carboxy-3-phenylpropyl)-L-lysyl-L-proline.
- 22. A method of treating or controlling allergic conditions in a mammal comprising administering to a mammal in need of such treatment a pharmaceutically-effective amount of a compound of claim 1.
- 23. A method of treating or preventing thromboembolic diseases in a mammal comprising administering to a mammal in need of such treatment a pharmaceutically-effective amount of a compound according to claim 1 and a pharmaceutically-acceptable carrier.
Parent Case Info
This application is a continuation-in-part of U.S. Ser. No. 545,564, filed Oct. 26, 1983, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3978052 |
Stoss et al. |
Aug 1976 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0029587 |
Jun 1981 |
EPX |
Non-Patent Literature Citations (3)
Entry |
Hafliger et al., Iminodibenzyl and Related Compounds, Ciba Geigy, 1985, pp. 35-43. |
Gordon, Textbook "Psychopharmacological Agents, 1964, Academic Press, New York, N.Y. pp. 5-8. |
March, "Advanced Organic Chemistry", pp. 796-797, John Wiley and Sons, (1985). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
545564 |
Oct 1983 |
|